Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears DiaSorin Molecular VZV Test

NEW YORK – DiaSorin Molecular has received US Food and Drug Administration clearance for its Simplexa VZV Swab Direct assay to detect varicella-zoster virus (VZV) DNA from cutaneous and mucocutaneous swab specimens, the firm announced on Tuesday.

The CLIA moderate complexity assay is designed for use on Diasorin's Liaison MDX instrument, which leverages real-time PCR technology. The firm said the test complements its Simplexa VZV Direct kit, which uses cerebrospinal fluid samples.

It is not always possible to visually distinguish VZV lesions from herpes simplex virus lesions because the clinical presentation can be similar. Therefore, it's critical for labs to identify VZV infection to enable proper patient treatment and management, DiaSorin said.

"With this release, we now offer a comprehensive menu of VZV and HSV tests from cerebrospinal fluid, mucocutaneous swab specimens, and cutaneous swab specimens," Michelle Tabb, chief scientific officer at DiaSorin Molecular, said in a statement. She said that customers can run all of the tests at the same time.

The company had obtained CE marking for its Simplexa VZV Swab Direct assay in September.

 

 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.